ESMO - Madrid 2026: Breast Cancer Pro Portal

Home
Conferences
All Conferences ESMO - Madrid 2026 ESMO - Berlin 2026 GBCC 2026 SABCS 2025 GBCC 2025 SABCS 2024 SABCS 2023
Add Your Conference

DAILY UPDATES IN BREAST CANCER

Supported by Educational Grants from Menarini/Stemline and Novartis Global
Tentative Agenda

View Session

4534235

540RO - Ultrasensitive monitoring of early ctDNA dynamics during neoadjuvant treatment in early-stage triple-negative breast cancer: Pre-interim results from the B-STRONGER-I study

TBA Minutes

4:00 PM-

View Session

4534236

541RO - Hormone receptor (HR), PDL1, and stromal tumor-infiltrating lymphocytes (sTILs) predict pembrolizumab benefit in HER2-positive (HER2+) early stage breast cancer (EBC) in the phase II neoHIP trial

TBA Minutes

4:00 PM-

View Session

4534237

543RO - DESTINY-Breast11: MRI-assessed objective responses during (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in HER2+ (eBC)

TBA Minutes

4:00 PM-

View Session

4534255

1842O - Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)

TBA Minutes

4:00 PM-

View Session

4534277

1RO - Overall survival from the Phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy

TBA Minutes

4:00 PM-

View Session

4534286

2RO - Retrospective exploratory biomarker (BM) analyses from evERA (BC): A Phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with oestrogen receptor-positive, HER2-negative advanced BC in the post-CDK4/6 inhibitor (i) setting

TBA Minutes

4:00 PM-

View Session

4534288

3RO - 18F-FES PET–defined whole-body ER heterogeneity identifies endocrine responsiveness and predicts survival in ER+/HER2− Metastatic Breast Cancer (MBC): results of a prospective international clinical trial

TBA Minutes

4:00 PM-

View Session

4534252

545RO - Omission of adjuvant radiotherapy after breast-conserving surgery in systemically untreated older patients with early-stage estrogen receptor positive breast cancer: 5-year results of the TOP-1 study (BOOG 2016-01)

TBA Minutes

4:00 PM-

View Session

4510984

LBA24 - Final Analysis of NRG Oncology/NSABP B-42, a Randomized, Double-blinded, Placebo-controlled Trial of Extended Letrozole in Postmenopausal Women with Hormone-receptor Positive Breast Cancer Who Have Completed Previous Adjuvant Therapy

TBA Minutes

4:00 PM-

View Session

4511021

LBA25 - Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes

TBA Minutes

4:00 PM-

View Session

4534238

LBA28 - Compression therapy using normal-sized surgical gloves for prevention of paclitaxel-induced peripheral neuropathy in breast cancer: results from the multicenter randomized AIUR trial

TBA Minutes

4:00 PM-

View Session

4534254

LBA14 - A Double-Blind Placebo Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for HER-2 Negative and Estrogen Receptor Positive (ER+) (MBC): Overall Survival Results of the CCTG/BCT MA.40/FINER Study (NCT04650581)

TBA Minutes

4:00 PM-

View Session

4534256

LBA26 - Short-term preoperative durvalumab for stage I TNBC: first results from the phase II UNLOCK 14 - POP-DURVA trial

TBA Minutes

4:00 PM-

View Session

4534259

LBA15 - Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study

TBA Minutes

4:00 PM-

View Session

4534276

LBA16 - VIKTORIA-1: Updated results of a randomized, open-label, phase 3 study of gedatolisib (geda) + fulvestrant (fulv) ± palbociclib (palbo) vs standard of care in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (Study 2)

TBA Minutes

4:00 PM-

View Session

4534287

LBA17 - HER2-PET imaging to predict trastuzumab deruxtecan (T-DXd) efficacy in advanced breast cancer: The phase II PREDICT-HER trial

TBA Minutes

4:00 PM-

View Session

4534289

LBA27 - APEX-Breast01: TQB2102 versus chemotherapy in HER2-low recurrent or metastatic breast cancer (r/m BC) : Results from a randomized phase 3 study

TBA Minutes

4:00 PM-

View Session

4511024

544RO - Final analysis of the GIM3 FATA trial: treatment schedule and three aromatase inhibitors (AIs) comparison in postmenopausal HR-positive (HR+) early breast cancer (eBC)

TBA Minutes

4:00 PM-

View Session

4510983

LBA13 - Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): a randomized, phase 3 study (HORIZON-Breast06)

TBA Minutes

4:00 PM-

View Session

4534290

1766RO - Health-Related Quality of Life from HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as 1L Maintenance Therapy for HER2+ mBC

TBA Minutes

4:00 PM-

View Session

4534291

4639RO - Final OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: Phase III OptiTROP-Breast01

TBA Minutes

4:00 PM-

View Session

4534292

4RO - Target switching with conserved-payload novel ADCs in patients with metastatic breast cancer following prior ADC therapy (SWITCH): a prospective, open-label, phase 2 platform trial

TBA Minutes

4:00 PM-

View Session

4534293

5RO - Safety and efficacy of SYS6043, a Novel B7-H3–Targeting Antibody-Drug Conjugate, in Patients with Advanced breast cancer

TBA Minutes

4:00 PM-

View Session

4534294

4640RO - Bulumtatug Fuvedotin (BFv, 9MW2821), a Nectin-4–Directed Antibody-Drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer Previously Treated with (TopI)-Based ADCs: Results from a Phase 2 Study

TBA Minutes

4:00 PM-

View Session

4534295

1767RO - BRIDGET: A Phase II trial of tucatinib added to trastuzumab/pertuzumab or ado-trastuzumab emtansine after isolated intracranial progression in patients with advanced HER2-positive breast cancer

TBA Minutes

4:00 PM-

View Session

4534297

1768RO - Radiation Therapy Followed by Intrathecal (IT) Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Metastasis: Results from a Phase II Multi-Institutional Study, (INSPIRE-LM)

TBA Minutes

4:00 PM-

View Session

4511023

LBA50 - PANKU-Breast01: Randomized Phase III Study of Izalontamab Brengitecan (iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic (LA/M) Hormone Receptor-Positive/HER2-negative (HR+/HER2-) Breast Cancer (BC)

TBA Minutes

4:00 PM-

View Session

4534253

LBA51 - Results From KEYNOTE-B49: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (Pembro) vs Placebo (Pbo) Plus Chemotherapy (CT) in Participants (Pts) With HR+/HER2− Advanced Breast Cancer (ABC)

TBA Minutes

4:00 PM-

View Session

4534257

LBA96 - First-line (1L) (Dato-DXd) vs chemotherapy in patients (pts) with locally recurrent inoperable or (mTNBC) for whom immunotherapy was not an option: Exploratory analysis of pts with brain metastases in TROPION-Breast02

TBA Minutes

4:00 PM-

View Session

4534298

LBA49 - A DESTINY-Breast09 (DB-)09 analysis of trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC) and baseline (BL) brain metastases (BMs)

TBA Minutes

4:00 PM-

View Session

4534299

1769RO - CTC characterization with the DETECT CTC score predicts therapy response in triple-positive aBC: Translational results of the Phase III DETECT V Study

TBA Minutes

4:00 PM-

View Session

4534300

1770RO - Ultra-sensitive MRD Assessment in Long-term Complete Responders to Anti-HER2 Therapy in HER2-positive Metastatic Breast Cancer: Initial Results from HER2-CR Study

TBA Minutes

4:00 PM-

View Session

4531559

538RO - Patient (pt)-reported outcomes (PROs) from the Phase III lidERA Breast Cancer (BC) trial of giredestrant (GIRE) in pts with oestrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC)

TBA Minutes

4:00 PM-

View Session

4531562

539RO - Patient-Reported Outcomes (PROs) From DESTINY-Breast05: Health-Related Quality of Life (HRQoL) With Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Patients (Pts) With High-Risk HER2-Positive Early Breast Cancer (eBC)

TBA Minutes

4:00 PM-

View Session

4531564

542RO - Prognostic impact of postoperative ctDNA surveillance on relapse-free survival and molecular lead time in high-risk breast cancer: JCOG1204A1

TBA Minutes

4:00 PM-

View Session

4510982

LBA23 - Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer

TBA Minutes

4:00 PM-

Encore Medical Education

Encore Medical Education provides expert-led breast cancer conference highlights. Stay informed with cutting-edge research and KOL insights.

Contact Info

Offices in USA and Spain

Breastconferences@encoremeded.com

Sign Up

Contact me when new conference highlights are posted!

Email Address

© 2026 Encore Medical Education. All Rights Reserved.

Terms & Conditions

Copy to Clipboard